Table 2.
Comparison of demographics and clinical data between patients with rheumatoid arthritis and healthy volunteers.
| Variable | Healthy Volunteers (N = 20) |
Patients with Rheumatoid Arthritis (N = 40) |
p |
|---|---|---|---|
| Age (mean years ± SD) | 48.0 ± 6.8 | 50.6 ± 10.2 | 0.144 |
| Sex (F:M) | 15:5 | 31:9 | >0.999 |
| RF positivity | - | 65.7% (26/40) | |
| ACPA positivity | - | 65.7% (23/35) | |
| DAS28-ESR | 3.19 ± 1.05 | ||
| CRP (mg/dL) | - | 0.56 ± 0.79 | |
| Medication | |||
| Corticosteroids | - | 87.5% (35/40) | |
| Salazopyrine | - | 72.5% (29/40) | |
| MTX | - | 80.0% (32/40) | |
| Leflunomide | - | 10.0% (4/40) | |
| Biologics | - | 67.5% (27/40) |
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; MTX, methotrexate; RF, rheumatoid factor; SD, standard deviation, - not available; biologics including etanercept, adalimumab, golimumab, tocilizumab, tofacitinib, and rituximab.